Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

Results from a phase I trial showed that glofitamab, a CD20-targeting T-cell–engaging bispecific antibody, has favorable activity and a manageable safety profile among patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Among the 171 patients in the trial, 74.3% had diffuse large B-cell lymphoma, transformed follicular lymphoma, or other aggressive histology.